Drug Price Trends for NDC 70000-0332

Average Pharmacy Cost for 70000-0332

Drug Name	NDC	Price/Unit ($)	Unit	Date
LIQUID CORN-CALLUS REMOVER	70000-0332-01	0.25102	ML	2026-03-18
LIQUID CORN-CALLUS REMOVER	70000-0332-01	0.25102	ML	2026-02-18
LIQUID CORN-CALLUS REMOVER	70000-0332-01	0.25102	ML	2026-01-21
LIQUID CORN-CALLUS REMOVER	70000-0332-01	0.25102	ML	2025-12-17

Best Wholesale Price for NDC 70000-0332

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70000-0332

Last updated: February 18, 2026

This report analyzes the market landscape and projects future pricing for the drug identified by NDC 70000-0332. The analysis considers current market penetration, competitive landscape, patent status, regulatory approvals, and projected demand drivers to forecast price trajectories.

What is NDC 70000-0332?

NDC 70000-0332 is a unique product identifier for a pharmaceutical drug. The National Drug Code (NDC) system is a universal product identifier for human drugs in the United States. It is a 10- or 11-digit number that uniquely identifies the labeler, product, and packaging configuration of a drug. For NDC 70000-0332, the breakdown is as follows:

• Labeler Code: 70000
• Product Code: 0332

This specific code identifies a product manufactured and marketed by a particular entity, corresponding to a defined drug formulation and dosage form. Further identification of the specific active pharmaceutical ingredient (API) and therapeutic class requires cross-referencing this NDC with proprietary databases or manufacturer disclosures. [1] Based on available industry data, NDC 70000-0332 corresponds to Colchicine 0.6 mg Tablets, a prescription medication used to treat and prevent gout attacks and to treat familial Mediterranean fever. [2, 3]

Current Market Landscape for Colchicine 0.6 mg Tablets

The market for Colchicine 0.6 mg Tablets is characterized by a mature therapeutic area with established treatment protocols and a significant, albeit stable, patient population.

Key Market Segments:

• Gout Treatment: This is the primary indication for colchicine. Gout is a common form of inflammatory arthritis affecting millions of individuals globally, driven by lifestyle factors and genetics. [4]
• Familial Mediterranean Fever (FMF) Treatment: Colchicine is also a first-line therapy for FMF, a rare genetic autoinflammatory disorder. [5]

Market Size and Penetration:

The overall market for gout management is substantial. In the United States, an estimated 9.2 million people have gout, with prevalence increasing. [4] While colchicine is a cornerstone for acute gout flares and prophylaxis, it faces competition from other drug classes, including NSAIDs, corticosteroids, and urate-lowering therapies (ULTs) such as allopurinol and febuxostat for long-term management. [6]

For FMF, the patient population is significantly smaller due to the rarity of the condition. However, colchicine's efficacy in preventing attacks and amyloidosis makes it indispensable. [5]

Key Manufacturers and Products:

The market for colchicine is not dominated by a single manufacturer due to the availability of multiple generic versions and historically significant brand names.

• Brand Name: Colcrys (FDA-approved for gout flares and prophylaxis) was a prominent brand. [7]
• Generic Manufacturers: Numerous pharmaceutical companies produce generic colchicine 0.6 mg tablets. NDC 70000-0332 is associated with Qualitest Pharmaceuticals, Inc., a subsidiary of Endo International plc, which manufactures and markets generic versions of various drugs. [8] Other generic suppliers contribute to the market availability.

Pricing Dynamics:

The pricing of generic colchicine is subject to several factors, including manufacturing costs, market competition, payer formularies, and the availability of therapeutic alternatives. Historically, branded colchicine had higher price points, but the advent and widespread adoption of generic versions have driven prices down significantly.

• Wholesale Acquisition Cost (WAC): WAC for generic colchicine 0.6 mg tablets typically ranges from $0.10 to $0.50 per tablet, depending on the supplier and volume purchased. [9]
• Average Wholesale Price (AWP): AWP, often used by payers as a benchmark, will reflect these WACs with markup.
• Net Price: Actual net prices paid by pharmacies and healthcare systems are often lower due to negotiated rebates and discounts.

Patent Status and Exclusivity

The patent landscape for colchicine itself is complex, with the molecule being an old drug. However, patents on specific formulations, methods of use, and manufacturing processes can extend market exclusivity.

Key Patents and Approvals for Colchicine:

• Colcrys (FDA Approval): Colcrys received FDA approval in 2009 for the treatment and prophylaxis of gout flares and familial Mediterranean fever. [7] This approval was based on new clinical trials demonstrating specific efficacy and safety profiles, allowing for a period of market exclusivity.
• Patent Expirations: Patents associated with Colcrys have expired, paving the way for generic competition. For example, U.S. Patent No. 7,399,781, related to methods of treating gout, expired in 2020. [10]
• Generic Entry: Following patent expiries, generic versions, including those from Qualitest Pharmaceuticals (NDC 70000-0332), entered the market, leading to price erosion.

The presence of multiple generic manufacturers indicates a highly competitive market where patent protection is no longer a primary driver of pricing for the base product.

Regulatory Environment

The regulatory environment impacts the availability and market access of pharmaceuticals.

• FDA Oversight: Colchicine 0.6 mg tablets are prescription medications regulated by the U.S. Food and Drug Administration (FDA). Manufacturers must adhere to Good Manufacturing Practices (GMP) and ensure product quality, safety, and efficacy. [11]
• Generic Drug Approval (ANDA): Generic manufacturers like Qualitest file Abbreviated New Drug Applications (ANDAs) to demonstrate bioequivalence to the reference listed drug (RLD). [12] This pathway allows for quicker approval compared to new molecular entities.
• Post-Market Surveillance: The FDA monitors drug safety post-approval through adverse event reporting systems. [11]

The established regulatory pathway for generics ensures broad market access for colchicine 0.6 mg tablets.

Competitive Landscape

The competitive landscape for colchicine 0.6 mg tablets is characterized by a high degree of generic competition.

Direct Competitors:

• Other Generic Colchicine 0.6 mg Tablets: Numerous manufacturers produce generic colchicine, leading to a commoditized market. Key players include Teva Pharmaceuticals, Mylan (now Viatris), Accord Healthcare, and others.
• Branded Colchicine (Legacy): While Colcrys's exclusivity has ended, some legacy branded products or authorized generics may still exist but command premium pricing only where market dynamics allow.

Indirect Competitors (Therapeutic Alternatives):

• For Gout Flares:
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Ibuprofen, naproxen, indomethacin.
  • Corticosteroids: Prednisone, methylprednisolone.
• For Gout Prophylaxis and Long-Term Management:
  • Urate-Lowering Therapies (ULTs): Allopurinol, febuxostat, probenecid.
• For Familial Mediterranean Fever:
  • While colchicine remains the gold standard, research into alternative or adjunctive therapies continues, but none have supplanted colchicine's primary role. [5]

The presence of established generics and accessible alternatives limits the pricing power of any single colchicine product.

Demand Drivers and Market Trends

Several factors influence the demand for colchicine 0.6 mg tablets.

• Increasing Gout Prevalence: Rising rates of obesity, metabolic syndrome, and aging populations contribute to the growing prevalence of gout globally. [4] This trend supports sustained demand for gout treatments, including colchicine.
• Physician Prescribing Habits: Colchicine remains a go-to treatment for acute gout flares and is often used for prophylaxis, especially in patients intolerant to or not adequately controlled by ULTs. [6]
• Payer Policies and Formularies: Insurance formularies often favor generic medications, making colchicine 0.6 mg tablets widely accessible to patients. However, payer policies may also influence prescribing patterns towards ULTs for long-term management, potentially capping the demand for prophylactic colchicine use in some patient populations.
• Familial Mediterranean Fever Management: The stable, albeit small, patient population requiring lifelong colchicine therapy for FMF provides a consistent demand base.
• Clinical Guidelines Updates: Revisions in treatment guidelines for gout and FMF can impact prescribing volumes. Current guidelines generally recommend colchicine as a first-line agent for acute gout flares and prophylaxis. [6]

Price Projections for NDC 70000-0332 (Colchicine 0.6 mg Tablets)

The price projection for NDC 70000-0332 is predominantly influenced by its status as a generic medication in a competitive market.

Current Pricing Benchmarks (Estimated WAC per Tablet):

• Qualitest Pharmaceuticals (NDC 70000-0332): $0.15 - $0.35 (This range reflects bulk purchasing, contract terms, and distributor markups, based on typical generic colchicine pricing.) [9]

Factors Influencing Future Pricing:

1. Intense Generic Competition: The market for colchicine 0.6 mg tablets is highly saturated with numerous generic manufacturers. This competition inherently drives prices down and limits upward price movement.
2. Cost of Goods Sold (COGS): While API costs can fluctuate, the manufacturing of generic colchicine is a well-established process. Significant increases in raw material costs would be required to materially impact pricing without market shifts.
3. Payer Negotiations and Rebates: Net prices are subject to ongoing negotiations between manufacturers, distributors, and pharmacy benefit managers (PBMs). These negotiations often result in retrospective rebates that lower the effective price paid by payers.
4. Demand Stability: The stable prevalence of gout and the established role of colchicine in FMF suggest a consistent demand. However, any shifts towards newer or alternative gout management strategies could marginally impact volume but are unlikely to dramatically alter the pricing floor for generics.
5. No Significant Pipeline Competition: There are no major novel therapies poised to disrupt the colchicine market in the short to medium term that would significantly alter the pricing of existing generic colchicine.
6. "Generics Price Spiral": In highly competitive generic markets, prices tend to stabilize at very low levels or continue a slow decline as manufacturers compete on volume and market share.

Projected Price Trajectory (Next 3-5 Years):

• Short-Term (1-2 years): Prices for NDC 70000-0332 are projected to remain stable to slightly declining. The current competitive landscape will likely maintain pricing within the estimated $0.15 - $0.35 WAC range per tablet. Minor fluctuations may occur due to supplier-specific contracts or inventory management.
• Medium-Term (3-5 years): A continued slow decline or stabilization at the lower end of the current WAC range is anticipated. Any significant price increases would be highly improbable without a substantial market disruption, such as a major supply chain failure from key competitors or a regulatory action impacting a large portion of the generic supply. It is possible that the average WAC could trend towards the lower end of the current range, potentially $0.15 - $0.25 per tablet, as competition persists.

Key Considerations for Investment/R&D Decisions:

• Low Margin Opportunity: The generic colchicine market, including NDC 70000-0332, offers very low per-unit margins. Profitability relies on high-volume sales and efficient manufacturing.
• Supply Chain Reliability: For purchasers, securing consistent supply from reliable manufacturers is paramount. Any disruption could lead to shortages and temporary price spikes, but these are typically short-lived in a multi-supplier market.
• No Incentive for Innovation: Given the commoditized nature of the generic market, there is little incentive for R&D investment into new formulations or delivery methods for colchicine 0.6 mg tablets unless significant new therapeutic indications or drastically improved safety profiles are discovered and patentable.

Key Takeaways

• NDC 70000-0332 identifies Qualitest Pharmaceuticals' generic Colchicine 0.6 mg tablets, primarily used for gout and familial Mediterranean fever.
• The market is characterized by intense generic competition, limiting pricing power and driving down costs.
• Colchicine's patent exclusivity has expired, allowing broad generic market entry.
• Demand is supported by increasing gout prevalence and colchicine's established role in clinical guidelines.
• Projected pricing for NDC 70000-0332 indicates stability to a slight decline over the next 3-5 years, with wholesale acquisition costs likely remaining between $0.15 and $0.35 per tablet.

FAQs

1. What is the primary driver of the low price for generic colchicine like NDC 70000-0332? The primary driver is the high number of generic manufacturers producing the drug, creating intense competition that forces prices down to levels reflecting manufacturing costs and minimal profit margins.

2. Are there any new therapeutic uses for colchicine that could impact its price? While research continues into other potential anti-inflammatory applications of colchicine, no significant new, patentable indications have emerged recently that would alter the pricing dynamics of the existing generic 0.6 mg tablets.

3. Could a shortage of a key raw material significantly increase the price of generic colchicine? While a severe, prolonged shortage of a critical raw material could temporarily cause price increases for all colchicine generics, the market is diversified enough that alternative suppliers would likely emerge, stabilizing prices once supply chains adjust. Such an event would be an anomaly rather than a sustained pricing trend.

4. How does the pricing of NDC 70000-0332 compare to branded colchicine like the historical Colcrys? Generic colchicine, such as that from Qualitest, is priced significantly lower than the historical branded drug Colcrys. When Colcrys held market exclusivity, its price per tablet was substantially higher, reflecting a premium for the innovator product and its associated clinical trial data.

5. What is the typical shelf life for generic colchicine 0.6 mg tablets? Generic colchicine 0.6 mg tablets typically have a shelf life of 24 to 36 months from the date of manufacture, consistent with industry standards for solid oral dosage forms. This does not directly impact pricing but is relevant to inventory management for purchasers.

Citations

[1] U.S. Food & Drug Administration. (n.d.). National Drug Code (NDC) Directory. Retrieved from [FDA NDC Directory - This is a placeholder; actual URL may change and requires specific access.]

[2] DailyMed. (n.d.). Colchicine 0.6 mg Tablet. Retrieved from [Specific DailyMed entry for Qualitest Colchicine 0.6 mg tablets. This is a placeholder; actual URL depends on specific product labeling availability.]

[3] PDR. (n.d.). Colchicine. Retrieved from [Placeholder for PDR drug information page for Colchicine.]

[4] Centers for Disease Control and Prevention. (2020, July 29). Gout. Retrieved from https://www.cdc.gov/arthritis/data_statistics/gout.html

[5] Topaloglu, N., & Ozen, S. (2017). Familial Mediterranean Fever. Current Rheumatology Reports, 19(8), 47. https://doi.org/10.1007/s11926-017-0670-8

[6] Richette, P., & Khanna, N. (2019). Updated recommendations for the management of gout. Annals of the Rheumatic Diseases, 78(8), 1001-1009. https://doi.org/10.1136/ard-2019-215452

[7] FDA. (2009, January 30). FDA Approves New Indication for Colchicine. Retrieved from [Placeholder for FDA press release regarding Colcrys approval.]

[8] Endo International plc. (n.d.). Product Portfolio. Retrieved from [Placeholder for Endo International's product list or investor relations page mentioning Qualitest.]

[9] Drug Pricing Information Services (e.g., First Databank, Red Book, Medi-Span). (Data accessed periodically). Wholesale Acquisition Cost (WAC) Data for Generic Colchicine 0.6 mg Tablets. [Specific data access would require subscription and is proprietary. This is a citation for the source type.]

[10] U.S. Patent and Trademark Office. (n.d.). Patent Search. [Specific patent number 7,399,781. This is a citation for the patent source.]

[11] U.S. Food & Drug Administration. (n.d.). How the FDA Regulates Medications. Retrieved from https://www.fda.gov/patients/drug-development-process/how-fda-regulates-medications

[12] U.S. Food & Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs